{
    "ticker": "CXDO",
    "name": "Cortexyme, Inc.",
    "description": "Cortexyme, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. Founded in 2015, Cortexyme aims to address the underlying causes of these conditions by targeting specific pathogens and neuroinflammatory pathways that contribute to cognitive decline. The company's lead product candidate, COR388, is an oral small molecule designed to inhibit the activity of the periodontal pathogen, Porphyromonas gingivalis, which is believed to play a significant role in the progression of Alzheimer's disease. Cortexyme is dedicated to advancing its research and clinical programs through rigorous scientific investigation and collaboration with leading researchers in the field. The company is committed to providing hope for patients and families affected by neurodegenerative diseases, striving to improve the quality of life for those suffering from these debilitating conditions. As Cortexyme continues to progress through clinical trials, it aims to bring innovative treatments to market that can alter the course of Alzheimer's disease and potentially other neurodegenerative disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.cortexyme.com",
    "ceo": "Brian G. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/Cortexyme",
        "linkedin": "https://www.linkedin.com/company/cortexyme/"
    },
    "investor_relations": "https://investors.cortexyme.com",
    "key_executives": [
        {
            "name": "Brian G. McGowan",
            "position": "CEO"
        },
        {
            "name": "James E. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "COR388"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cortexyme, Inc. | Innovative Therapies for Neurodegenerative Diseases",
        "meta_description": "Learn about Cortexyme, Inc., a biopharmaceutical company dedicated to developing therapies for Alzheimer's disease and other neurodegenerative conditions.",
        "keywords": [
            "Cortexyme",
            "Alzheimer's Disease",
            "Neurodegenerative Diseases",
            "COR388",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Cortexyme focused on?",
            "answer": "Cortexyme is focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease."
        },
        {
            "question": "What is COR388?",
            "answer": "COR388 is Cortexyme's lead product candidate aimed at inhibiting the activity of the pathogen Porphyromonas gingivalis."
        },
        {
            "question": "Where is Cortexyme headquartered?",
            "answer": "Cortexyme is headquartered in San Francisco, California, USA."
        },
        {
            "question": "When was Cortexyme founded?",
            "answer": "Cortexyme was founded in 2015."
        }
    ],
    "competitors": [
        "ADVM",
        "AXSM",
        "PTCT",
        "SAVA"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "MRNA"
    ]
}